Programs

Our fearless pursuit of science, guided by in-depth translational research, aims to address unmet needs for patients with limited treatment options.

KRAS Inhibitors

The journey to create KRAS inhibitors has been ongoing for over three decades.^1,2 Our experienced team is rigorously advancing discovery and development programs targeting the KRAS^G12C, KRAS^G12D and other KRAS mutations.

Explore our KRAS programs

MRTX1719

MRTX1719 is an investigational, internally discovered synthetic lethal PRMT5 inhibitor for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.

Explore our MRTX1719 program